STAT+: HHS tries pushing pharma to the negotiating desk
Need to keep on prime of the science and politics driving biotech right now? Enroll to get our biotech publication in your inbox.
Good morning. At the moment, we’re listening to extra about President Trump’s “most-favored nation” plan for drug pricing, Recursion’s case for why the corporate laid off 20% of its employees, and extra.
HHS tries pushing pharma to the negotiating desk
The Trump administration is pressuring pharmaceutical firms to barter drug costs all the way down to ranges seen in different rich nations, invoking a “most-favored nation” clause as leverage. Whereas business executives await specifics on which medicine and worth targets could possibly be in play, the Division of Well being and Human Providers is insisting firms have already got the steerage they want, STAT’s Daniel Payne stories.
